J&J Divests OTC Anti-Dandruff Product To Separate Buyers Across 3 Regions
This article was originally published in The Pink Sheet & The Rose Sheet
J&J agrees to sell marketing rights to its OTC 1% ketoconazole dandruff treatment product to Kramer Labs in the US and Latin America, to German firm Stada in the EMEA and to UK firm Alliance Pharma for the Asia-Pacific market as it continues to spin off non-core brands and focus on its core $1bn brands.
You may also be interested in...
With Nizoral A-D sample packages approved for distribution, Arcadia has opportunity to expand sales by providing samples which dermatologists and other doctors can offer and recommend to patients.
UK-based Alliance Pharma saw sales rise double-digits in 2021, with acquisitions bolstering the performance of its established brands. Going into 2022, the company says it is in a strong position to pursue M&A in the consumer health space.
Sanofi sells US rights to anti-diarrhea Kaopectate brand to Arcadia Consumer Healthcare, which plans to invest in marketing and innovation behind the brand. Arcadia also markets the Nizoral dandruff shampoo and Fungi-Nail consumer health brands.